Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway - PubMed (original) (raw)
Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway
Irina Daurkin et al. Cancer Res. 2011.
Abstract
Renal cell carcinoma (RCC), the most common human kidney cancer, is frequently infiltrated with tumor-associated macrophages (TAM) that can promote malignant progression. Here, we show that TAMs isolated from human RCC produce substantial amounts of the proinflammatory chemokine CCL2 and immunosuppressive cytokine IL-10, in addition to enhanced eicosanoid production via an activated 15-lipoxygenase-2 (15-LOX2) pathway. TAMs isolated from RCC tumors had a high 15-LOX2 expression and secreted substantial amounts of 15(S)-hydroxyeicosatetraenoic acid, its major bioactive lipid product. Inhibition of lipoxygenase activity significantly reduced production of CCL2 and IL-10 by RCC TAMs. In addition, TAMs isolated from RCC were capable of inducing in T lymphocytes, the pivotal T regulatory cell transcription factor forkhead box P3 (FOXP3), and the inhibitory cytotoxic T-lymphocyte antigen 4 (CTLA-4) coreceptor. However, this TAM-mediated induction of FOXP3 and CTLA-4 in T cells was independent of lipoxygenase and could not be reversed by inhibiting lipoxygenase activity. Collectively, our results show that TAMs, often present in RCCs, display enhanced 15-LOX2 activity that contributes to RCC-related inflammation, immunosuppression, and malignant progression. Furthermore, we show that TAMs mediate the development of immune tolerance through both 15-LOX2-dependent and 15-LOX2-independent pathways. We propose that manipulating LOX-dependent arachidonic acid metabolism in the tumor microenvironment could offer new strategies to block cancer-related inflammation and immune escape in patients with RCC.
Similar articles
- Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.
Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, Cascinu S. Santoni M, et al. Cancer Immunol Immunother. 2013 Dec;62(12):1757-68. doi: 10.1007/s00262-013-1487-6. Epub 2013 Oct 17. Cancer Immunol Immunother. 2013. PMID: 24132754 Free PMC article. Review. - 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
Matsuyama M, Yoshimura R, Mitsuhashi M, Tsuchida K, Takemoto Y, Kawahito Y, Sano H, Nakatani T. Matsuyama M, et al. Oncol Rep. 2005 Jul;14(1):73-9. Oncol Rep. 2005. PMID: 15944770 - Molecular understanding and clinical aspects of tumor-associated macrophages in the immunotherapy of renal cell carcinoma.
Liu H, Lv Z, Zhang G, Yan Z, Bai S, Dong D, Wang K. Liu H, et al. J Exp Clin Cancer Res. 2024 Aug 22;43(1):242. doi: 10.1186/s13046-024-03164-y. J Exp Clin Cancer Res. 2024. PMID: 39169402 Free PMC article. Review. - Tumor Progression Locus 2 (Tpl2) Activates the Mammalian Target of Rapamycin (mTOR) Pathway, Inhibits Forkhead Box P3 (FoxP3) Expression, and Limits Regulatory T Cell (Treg) Immunosuppressive Functions.
Li X, Acuff NV, Peeks AR, Kirkland R, Wyatt KD, Nagy T, Watford WT. Li X, et al. J Biol Chem. 2016 Aug 5;291(32):16802-15. doi: 10.1074/jbc.M116.718783. Epub 2016 Jun 3. J Biol Chem. 2016. PMID: 27261457 Free PMC article. - Tumor Associated Macrophages in Kidney Cancer.
Kovaleva OV, Samoilova DV, Shitova MS, Gratchev A. Kovaleva OV, et al. Anal Cell Pathol (Amst). 2016;2016:9307549. doi: 10.1155/2016/9307549. Epub 2016 Oct 11. Anal Cell Pathol (Amst). 2016. PMID: 27807511 Free PMC article. Review.
Cited by
- Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
Asai H, Fujiwara H, An J, Ochi T, Miyazaki Y, Nagai K, Okamoto S, Mineno J, Kuzushima K, Shiku H, Inoue H, Yasukawa M. Asai H, et al. PLoS One. 2013;8(2):e56820. doi: 10.1371/journal.pone.0056820. Epub 2013 Feb 18. PLoS One. 2013. PMID: 23441216 Free PMC article. - CCL2 as a potential therapeutic target for clear cell renal cell carcinoma.
Arakaki R, Yamasaki T, Kanno T, Shibasaki N, Sakamoto H, Utsunomiya N, Sumiyoshi T, Shibuya S, Tsuruyama T, Nakamura E, Ogawa O, Kamba T. Arakaki R, et al. Cancer Med. 2016 Oct;5(10):2920-2933. doi: 10.1002/cam4.886. Epub 2016 Sep 26. Cancer Med. 2016. PMID: 27666332 Free PMC article. - Autocrine MCP-1/CCR2 signaling stimulates proliferation and migration of renal carcinoma cells.
Küper C, Beck FX, Neuhofer W. Küper C, et al. Oncol Lett. 2016 Sep;12(3):2201-2209. doi: 10.3892/ol.2016.4875. Epub 2016 Jul 18. Oncol Lett. 2016. PMID: 27602164 Free PMC article. - A high-throughput mass spectrometric assay for discovery of human lipoxygenase inhibitors and allosteric effectors.
Jameson JB 2nd, Kenyon V, Holman TR. Jameson JB 2nd, et al. Anal Biochem. 2015 May 1;476:45-50. doi: 10.1016/j.ab.2015.02.011. Epub 2015 Feb 21. Anal Biochem. 2015. PMID: 25712042 Free PMC article. - Carbon dot-based nanomaterials: a promising future nano-platform for targeting tumor-associated macrophages.
Miao Y, Wang S, Zhang B, Liu L. Miao Y, et al. Front Immunol. 2023 May 2;14:1133238. doi: 10.3389/fimmu.2023.1133238. eCollection 2023. Front Immunol. 2023. PMID: 37205099 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical